Eisai Looks To New Drugs, Sales Expansions To Supplant Aricept Patent
This article was originally published in PharmAsia News
Executive Summary
Eisai expects product launches and increased sales of existing drugs to help it survive the loss of U.S. patent protection for its best-selling Aricept (donepezil) Alzheimer's disease drug later this year